Endostatin Inhibits the Vascular Endothelial Growth Factor-Induced Mobilization of Endothelial Progenitor Cells

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8345-8350

  Schuch, Gunter ^a   Heymach, John V ^a,b   Nomi, Masashi ^a   Machluf, Marcelle ^a   Force, Jeremy ^b   Atala, Anthony ^a   Eder Jr , Joseph P ^a   Folkman, Judah ^b   Soker, Shay ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; BETA GALACTOSIDASE; ENDOSTATIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD; BONE MARROW; CELL TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL;

ANIMALS; CELL MOVEMENT; ENDOSTATINS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346365369     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Folkman, J. Angiogenesis-dependent diseases. Semin. Oncol., 28: 536-542, 2001.
2. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
3. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., and Isner, J. M. Isolation of putative progenitor endothelial cells for angiogenesis. Science (Wash. DC), 275: 964-967, 1997.
4. Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Investig., 105: 17-19, 2000.
5. Stevens, T., Rosenberg, R., Aird, W., Quertermous, T., Johnson, F. L., Garcia, J. G., Hebbel, R. P., Tuder, R. M., and Garfinkel, S. NHLB1 workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am. J. Physiol. Cell Physiol., 281: C1422-C1433, 2001.
6. Moore, M. A. Putting the neo into neoangiogenesis. J. Clin. Investig., 109: 313-315, 2002.
7. Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer, 2: 826-835, 2002.
8. Solovey, A., Lin, Y., Browne, P., Choong, S., Wayner, E., and Hebbel, R. P. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med., 337: 1584-1590, 1997.
9. Sbarbati, R., de Boer, M., Marzilli, M., Scarlattini, M., Rossi, G., and van Mourik, J. A. Immunologic detection of endothelial cells in human whole blood. Blood, 77: 764-769, 1991.
10. Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A., and Rafii, S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 95: 952-958, 2000.
11. Solovey, A. N., Gui, L., Chang, L., Enenstein, J., Browne, P. V., and Hebbel, R. P. Identification and functional assessment of endothelial PIH12. J. Lab. Clin. Med., 138: 322-331, 2001.
12. Schlaeger, T. M., Bartunkova, S., Lawitts, J. A., Teichmann, G., Risau, W., Deutsch, U., and Sato, T. N. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc. Natl. Acad. Sci. USA, 94: 3058-3063, 1997.
13. Asahara, T., Musuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., and Isner, J. M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res., 85: 221-228, 1999.
14. Lyden, D., Young, A. Z., Zagzag, D., Yan, W., Gerald, W., O'Reilly, R., Bader, B. L., Hynes, R. O., Zhuang, Y., Manova, K., and Benezra, R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (Lond.), 401: 670-677, 1999.
15. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N. R., Crystal, R. G., Moore, M. A., Hajjar, K. A., Manova, K., Benezra, R., and Rafii, S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med., 7: 1194-1201, 2001.
16. Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., and Isner, J. M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J., 18: 3964-3972, 1999.
17. Gill, M., Dias, S., Hattori, K., Rivera, M. L., Hicklin, D., Witte, L., Girardi, L., Yurt, R., Himel, H., and Rafii, S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res., 88: 167-174, 2001.
18. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
19. Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segal, M., and Sukhatme, V. P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem., 274: 11721-11726, 1999.
20. Mundhenke, C., Thomas, J. P., Wilding, G., Lee, F. T., Kelzc, F., Chappell, R., Neider, R., Sebree, L. A., and Friedl, A. Tissue examination to monitor antiangiogenic therapy: a Phase I clinical trial with endostatin. Clin. Cancer Res., 7: 3366-3374, 2001.
21. Eder, J. P., Jr., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M. T., Janicek, M. J., Fogler, W. E., Schnipper, L., Kinchla, N., Sidor, C., Phillips, E., Folkman, J., and Kufe, D. W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol., 20: 3772-3784, 2002.
22. Herbst, R. S., Lee, A. T., Tran, H. T., and Abbruzzese, J. L. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr. Oncol. Rep., 3: 131-140, 2001.
23. Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., and Black, P. M. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol., 19: 35-39, 2001.
24. Schuch, G., Machluf, M., Bartsch, G., Jr., Nomi, M., Richard, H., Atala, A., and Soker, S. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood, 100: 4622-4628, 2002.
25. Reyes, M., Dudek, A., Jahagirdar, B., Koodie, L., Marker, P. H., and Verfaillie, C. M. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Investig., 109: 337-346, 2002.
26. Waters, W. R., Harkins, K. R., and Wannemuehler, M. J. Five-color flow cytometric analysis of swine lymphocytes for detection of proliferation, apoptosis, viability, and phenotype. Cytometry, 48: 146-152, 2002.
27. Laird, A. D., Christensen, J. G., Li, G., Carver, J., Smith, K., Xin, X., Moss, K. G., Louie, S. G., Mendel, D. B., and Cherrington, J. M. SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16: 681-690, 2002.
28. Rafii, S., Shapiro, F., Rimarachin, J., Nachman, R. L., Ferris, B., Weksler, B., Moore, M. A., and Asch, A. S. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood, 84: 10-19, 1994.
29. Capillo, M., Mancuso, P., Gobbi, A., Monestiroli, S., Pruneri, G., Dell'Agnola, C., Martinelli, G., Shultz, L., and Bertolini, F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res., 9: 377-382, 2003.
30. Takakura, N., Huang, X. L., Naruse, T., Hamaguchi, I., Dumont, D. J., Yancopoulos, G. D., and Suda, T. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity, 9: 677-686, 1998.
31. Monestiroli, S., Mancuso, P., Burlini, A., Pruneri, G., Dell'Agnola, C., Gobbi, A., Martinelli, G., and Bertolini, F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res., 61: 4341-4344, 2001.
32. Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H. P., Nguyen, T. N., Peers, D., Chisholm, V., Hillan, K. J., and Schwall, R. H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med., 4: 336-340, 1998.
33. Schuch, G., Kisker, O., Atala, A., and Soker, S. Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis, 5: 181-190, 2002.